FDA Accepts Innovative Drug Application – ImmunoMod, LLC Begins Diabetes Therapeutic Trials

Published: Jul 25, 2007

PHILADELPHIA--(BUSINESS WIRE)--ImmunoMod, LLC, a Charleston, SC-based biotechnology company, has received an FDA Orphan Drug Grant award for a Type 1 diabetes therapeutic and is beginning its first human patient trials at the Children’s Hospital of Philadelphia. ImmunoMod, a spin-off from the Medical University of South Carolina (MUSC), that is developing novel therapeutics to alleviate suffering caused by diabetes, was founded in 2006 by two nationally renowned MUSC pediatric physicians—Dr. Lyndon Key, department chair, and Dr. Inderjit Singh, PhD, scientific director of the Children's Research Institute—along with Charleston businessman Bob Faith, chairman and CEO of Greystar Real Estate Partners and South Carolina’s former Secretary of Commerce.

Back to news